Cargando…

Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?

There is increasing evidence for beneficial effects of early DMARD (disease-modifying antirheumatic drug) therapy over delayed treatment in patients who present with arthritis of recent onset. However, no universal consensus exists concerning the choice of initial drug or whether single drugs or com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Machold, Klaus P, Nell, Valerie PK, Stamm, Tanja A, Smolen, Josef S
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526637/ https://www.ncbi.nlm.nih.gov/pubmed/16719936 http://dx.doi.org/10.1186/ar1966

Ejemplares similares

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
por: Aletaha, Daniel, et al.
Publicado: (2005)

Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure
por: Kapral, Theresa, et al.
Publicado: (2006)

Remission by composite scores in rheumatoid arthritis: are ankles and feet important?
por: Kapral, Theresa, et al.
Publicado: (2007)

Autoantibodies in very early rheumatoid arthritis: diagnostic tools or pathogenic players?
por: Steiner, G, et al.
Publicado: (2003)

The diagnostic significance of autoantibodies in patients with very early rheumatoid arthritis
por: Nell, V, et al.
Publicado: (2003)

Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohort
por: Biliavska, Iuliia, et al.
Publicado: (2013)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis
por: Verstappen, M., et al.
Publicado: (2020)

Effects of a brief workplace-centered consultation for employees with musculoskeletal pain on health outcomes: a prospective cohort study
por: Leiss, Harald, et al.
Publicado: (2019)

Value of self-performed joint counts in rheumatoid arthritis patients near remission
por: Radner, Helga, et al.
Publicado: (2012)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Prediagnosis radiological progression in rheumatoid arthritis: a novel tool to study the effects of early DMARD therapy
por: Wick, MC, et al.
Publicado: (2004)

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
por: Stamm, Tanja Alexandra, et al.
Publicado: (2018)

Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study
por: De La Fuente, Fanny, et al.
Publicado: (2022)

Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone
por: Edwards, Carl K., et al.
Publicado: (2012)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
por: Cho, Soo-Kyung, et al.
Publicado: (2017)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
por: Wei, Kai, et al.
Publicado: (2022)

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
por: Jeon, Chan Hong
Publicado: (2022)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis
por: Peterson, Jeffrey D, et al.
Publicado: (2010)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy
por: Provan, Sella Aarrestad, et al.
Publicado: (2020)

Doubtful swelling on clinical examination reflects synovitis in rheumatoid arthritis
por: Mandl, Peter, et al.
Publicado: (2020)

The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2014)

Abnormal liver function tests in inflammatory arthritis: think beyond the DMARDs
por: Fahmy, Alexander, et al.
Publicado: (2018)

Healthcare professionals’ perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis
por: Voshaar, M. J. H., et al.
Publicado: (2022)

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Nathalie, Luurssen-Masurel, et al.
Publicado: (2021)

A 4-year non-randomized comparative phase-IV study of early rheumatoid arthritis: integrative anthroposophic medicine for patients with preference against DMARDs versus conventional therapy including DMARDs for patients without preference
por: Hamre, Harald J, et al.
Publicado: (2018)

Patient education, disease activity and physical function: can we be more targeted? A cross sectional study among people with rheumatoid arthritis, psoriatic arthritis and hand osteoarthritis
por: Drăgoi, Răzvan G, et al.
Publicado: (2013)

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
por: Humby, Frances, et al.
Publicado: (2019)

Aspects of early arthritis. Biological therapy in early arthritis – overtreatment or the way to go?
por: Ikeda, Kei, et al.
Publicado: (2007)

American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision
por: Studenic, Paul, et al.
Publicado: (2023)

American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision
por: Studenic, Paul, et al.
Publicado: (2022)

Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis
por: Bae, Sang-Cheol, et al.
Publicado: (2013)

A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases
por: Kastrati, Kastriot, et al.
Publicado: (2022)

Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?
por: Pasma, Annelieke, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1dasv19p5704s3882doomiqj79